Since the immune-checkpoint PD-1L increases the glycolysis in cancer cells by activating Akt/mTOR pathway, the use of immune-checkpoint inhibitors may relieve the competition for glucose between cancer cells and T-lymphocytes [98], restoring the anti-tumor efficiency of the latter. This evidence concerns the gene MTOR and cancer.